Breast cancer is not a single disease but a family of molecularly distinct malignancies that share the common feature of uncontrolled growth of cells within the breast. The breast is composed of glandular tissue (lobules that produce milk), ducts that carry milk to the nipple, fatty tissue, and supporting connective tissue — and cancer can arise from any of these structures, though the vast majority originate in the ductal epithelium. When cells in these structures accumulate enough genetic mutations to override the normal cell-cycle checkpoints that control division and programmed cell death (apoptosis), they begin to replicate without restraint, eventually forming a detectable tumour.

At the molecular level, breast cancer development is a multi-step process that typically unfolds over years or decades. The first step involves an initiating mutation — often in BRCA1, BRCA2, TP53, PIK3CA, or the PTEN tumour suppressor — either inherited from a parent or acquired through DNA damage from radiation, carcinogenic chemicals, or the cumulative errors of normal cell replication. A single mutation is rarely sufficient; cancer requires the accumulation of several cooperating mutations. The critical second step is promotion — an environment that encourages the mutated cell to replicate preferentially. Oestrogen is the primary driver in the most common breast cancers: it binds oestrogen receptors on ductal cells and acts as a proliferative signal, stimulating cell division and thereby increasing the probability that further mutations will accumulate. This is why oestrogen metabolism — specifically how efficiently the body converts oestradiol into protective 2-hydroxy metabolites rather than genotoxic 4-hydroxy and 16-alpha-hydroxy metabolites — is so central to functional medicine’s approach to both breast cancer risk reduction and post-treatment recovery.

From a functional medicine perspective, breast cancer risk is not a binary genetic destiny but a biological landscape shaped by modifiable factors including oestrogen detoxification efficiency (governed by CYP1A2, CYP1B1, COMT, and MTHFR enzyme function), insulin and IGF-1 signalling, adipose tissue mass (which produces oestrogen via aromatase enzyme activity), chronic systemic inflammation, gut microbiome composition (the “estrobolome” — gut bacteria that regulate oestrogen reabsorption), and cumulative exposure to environmental xenoestrogens in plastics, pesticides, and personal care products. Understanding and optimising each of these dimensions is the foundation of integrative breast cancer support at Patients Medical.

Breast cancer is the most commonly diagnosed cancer in women worldwide, accounting for approximately 30% of all new female cancer diagnoses in the United States each year. It occurs across all ages and ethnicities, though risk increases significantly after age 40, and it can — less commonly — also affect men, who account for approximately 1% of breast cancer diagnoses. Encouragingly, earlier detection through mammographic screening and improved systemic therapies have dramatically improved outcomes: when detected at Stage I, the five-year relative survival rate exceeds 99%.